Why Cubist Pharmaceuticals Inc. Shares Jumped
Cubist shares soar after announcing positive late-stage data for a key pipeline drug. Should shareholders expect more upside or is now the time to ring the register?
Is This Cubist's Biggest Opportunity?
The war on microbes has an important ally. Cubist Pharmaceuticals (Nasdaq: CBST) has a $1 billion antibiotic franchise and is getting ready to launch another. It also has partnerships with big pharmas AstraZeneca (NYSE: AZN) and Novartis (NYSE: NVS).